On January 7, 2026, Soley Therapeutics, a science-first, tech-enabled drug discovery and development company, announced a $200 million Series C financing to advance its proprietary cell stress sensing platform and pipeline of novel therapeutics into the clinic. New investors in this round included Surveyor Capital as primary investor, joined by HRTG Partners, RWN Management, and others. Existing Soley investors, including Doug Leone Family Fund, Breyer Capital, and GordonMD Global Investments® LP, and other undisclosed investors also participated. Wilson Sonsini Goodrich & Rosati advised Soley on the transaction.

The proceeds from the Series C will support IND-enabling work and clinical trials for two first-in-class internally discovered and developed oncology assets, in addition to advancement of the non-oncology stress-reducing drug candidates for neurodegenerative disorders and metabolic diseases, as well as continued platform scale-up.

The Wilson Sonsini team that advised Soley was led by partners Jocqui Kaup, Allison Spinner, and Julia Minitti.

For more information, please see Soley’s news release.